|Bid||1.8000 x 2900|
|Ask||2.1000 x 1100|
|Day's range||1.9000 - 2.0300|
|52-week range||1.7700 - 5.0400|
|Beta (5Y monthly)||2.06|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||8.64|
Cellectis, which gets a seat on Primera's board, will collaborate with Primera on the development of therapies for mitochondrial diseases, a group of genetic disorders. Under terms of the deal, if Primera chooses to exclusively license up to five co-developed therapies from Cellectis, it will be eligible to get up to $750 million in milestone payments.
Iovance Biotherapeutics (IOVA) reports a wider-than-expected loss in Q3. The company is on track to initiate a rolling BLA submission for lifileucel in melanoma later this month.
Iovance (IOVA) is progressing with its pipeline development. Management, after many delays, initiated a rolling BLA filing with the FDA for its lead candidate in metastatic melanoma.